A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:
Back to home » Top Stories » IAS 2009
IAC 2008 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
Cape Town, South Africa
July 19-22, 2009

Circumcision Protects Insertive MSM Partners

July 21, 2009

By Tim Horn

Circumcision may protect men who have sex with men (MSM) against HIV transmission via insertive anal intercourse, according to a cohort study conducted in Soweto, South Africa, and reported Monday, July 20, at the Fifth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town.

Three clinical trials conducted to date, randomizing heterosexual men to immediate or delayed circumcision, have found that circumcision lowers the risk of HIV acquisition by roughly two thirds. Until recently, it wasn’t known if the same benefit extends to men who engage in unprotected insertive anal sex with other men.

The Soweto Men’s Study, reported at IAS by Tim Lane, PhD, MPH, of the University of California at San Francisco and his colleagues, was a non-randomized cohort evaluation involving 378 MSM. Participants reported their sexual behavior with their last five partners, including positioning during anal intercourse (insertive, receptive or both) with men. Circumcision was self-reported, and HIV status was determined through rapid antibody testing.  

HIV prevalence stood at 13.2 percent, and 76.4 percent of the men reported engaging only in insertive anal intercourse. About 36 percent of the men participating in the cohort were circumcised.

In the analysis conducted by Lane’s group, the risk of infection among uncircumcised MSM reporting exclusive insertive anal intercourse with male partners was roughly 4.5 times higher than among circumcised men who reported exclusive insertive anal intercourse.

Lane’s group believes circumcision may be effective at reducing HIV transmission between men in high prevalence settings such as Soweto where MSM practice a high degree of sexual role segregation. To further explore this suggestion, however, a randomized clinical trial—much like those that have enrolled heterosexual men engaging exclusively in insertive vaginal sex—is necessary. But Lane also warns that the acceptability and ethical implications of male circumcision in MSM populations should be assessed before initiating such clinical trials.

Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 3 (of 3 total)    

xavier, Johannesburg, 2009-07-24 20:53:55
I think that the assumption that there is a high degree of sexual role segregation in MSM communities in Soweto to be a bit problematic. I am curious to know what evidence the researcher relied on to conclude that 76% of the men had insertive anal intercourse only, and one wonders how representative of a group of MSM this was.

Mike Arnold, Nicholasville, 2009-07-23 00:43:22
I must agree Frank, seems ironic today the US still has the highest rate of circumcision of any industrialized country. Yet still has the highest rate of HIV of any industrialized country.

Frank OHara, , 2009-07-21 20:55:35
This study directly conflicts with four previous studies carried out in Australia, New Zealand, The US and Great Britian that showed no benefit from male circumcision. How is it that this study found such a marked difference? With the falling infant male circumcision rate in The US, a raft of these studies has been coming out with breathless press releases ad infinitum. I predicted more than 10 years ago that there would be a lashback and my prediction is becoming true.

comments 1 - 3 (of 3 total)    

Funding for coverage of this conference is provided, in part, by an unrestricted educational grant from Tibotec Therapeutics, a division of Ortho Biotech Products, LP.
More from IAS 2009

Starting and Switching Treatment

July 31, 2009
South African Study: Nurses Comparable to Doctors in Monitoring HIV Management
July 30, 2009
Acyclovir Slows HIV Disease Progression, But Fails to Reduce HIV Transmission
July 27, 2009
Switch From Norvir-Boosted to Unboosted Reyataz Safe and Effective
July 24, 2009
Kaletra Is Better Than Viramune for Kids Exposed to Viramune at Birth
Study Hints That Micronutrient Supplement Might Help HIV-Positive Kids
A Quad NRTI Regimen Fails to Perform
July 23, 2009
HIV Treatment Effective Without Laboratory Monitoring in Southern Africa Study
Viramune Has Similar Efficacy to Reyataz
July 22, 2009
Pediatric Viramune May Still Work as Treatment in Kids Exposed at Birth
Triple-Drug Regimen Works Well for Heavily Treatment-Experienced Patients
Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment
People on Sustiva Have Less Risk for Treatment Failure Than People on Kaletra
Substantial Single-Year Gains in ARV Access in 2008
July 21, 2009
Isentress Going Strong After Three Years in Treatment Starters
More Than Half Could Need Treatment Within 2 Years of Infection
July 20, 2009
Pediatric HIV: Successes and Challenges
GRACE Shows Similar Treatment Response Rates in Women and Men on Prezista Treatment
CD4 Counts Key to AIDS-Free Survival While on HIV Treatment

Women and HIV

July 28, 2009
Menopause May Occur Earlier in HIV-Positive Women
July 24, 2009
No Transmission and Few Birth Defects in Babies Born to African Mothers on HIV Treatment
July 22, 2009
Mma Bana: Lowest-Ever Mother-to-Child HIV Transmission Rates With Combo Therapy in Botswana
July 20, 2009
GRACE Shows Similar Treatment Response Rates in Women and Men on Prezista Treatment

HIV/AIDS Complications

August 3, 2009
New Studies Question Abacavir Role in Heart Attack Risk
July 30, 2009
Perhaps More Lipodystrophy With Sustiva?
July 29, 2009
High Prevalence of Vitamin D Deficiency in HIV-Positive Men
July 28, 2009
Menopause May Occur Earlier in HIV-Positive Women
July 27, 2009
Chronic Stress and Non-AIDS Diseases—Is There a Link?
July 23, 2009
Zinc Supplements Prevent Immune Decline in Chronic Substance Users
Efavirenz, Race Linked to Vitamin D Deficiency
Cancer Rates Are Lower, but Still Present at Higher CD4 Levels
More Than Half of People With HIV Might Have Cognitive Impairment
July 22, 2009
ARV Therapy of Little Benefit in Preventing Anal Cancer
ARV Treatment Eases Cape Town TB Rates
July 21, 2009
ARV Treatment Protects Against Malaria in Ugandan Study

Experimental HIV Drugs

July 28, 2009
Once- vs. Twice-Daily Kaletra for Treatment Veterans
July 27, 2009
Two Studies Explore Switch to Boosted Prezista Monotherapy
July 22, 2009
Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment
July 21, 2009
Selzentry Comparable to Sustiva After 96 Weeks in Treatment Naives
Shionogi-GSK Integrase Inhibitor Shows Promise

HIV Transmission and Prevention

July 30, 2009
Acyclovir Slows HIV Disease Progression, But Fails to Reduce HIV Transmission
July 24, 2009
No Transmission and Few Birth Defects in Babies Born to African Mothers on HIV Treatment
July 22, 2009
Mma Bana: Lowest-Ever Mother-to-Child HIV Transmission Rates With Combo Therapy in Botswana
July 21, 2009
Circumcision Protects Insertive MSM Partners

Global HIV/AIDS

July 21, 2009
ARV Treatment Protects Against Malaria in Ugandan Study


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.